Table 2 Adverse event.
From: VRd vs. VPd as induction therapy in high risk newly diagnosed multiple myeloma
AE | VRd | VPd | p value |
|---|---|---|---|
bone marrow suppression, n (%) | 4(16) | 2(9.6) | 0.511 |
peripheral nerve damage, n (%) | 5(20) | 4(19) | 0.935 |
liver cell injury, n (%) | 1(4) | 0 | 0.266 |
thrombocytopenia, n (%) | 2(8) | 1(4.8) | 0.654 |
infection, n (%) | 1(4) | 1(4.8) | 0.9 |
gastrointestinal symptoms, n (%) | 1(4) | 1(4.8) | 0.9 |
fatigue, n (%) | 1(4) | 1(4.8) | 0.9 |
rash, n (%) | 0 | 4(19) | 0.024 |
